XERS (Xeris Biopharma Holdings) ROCE %: 11.57% (As of Mar. 2026)


XERS Xeris Biopharma Holdings Inc XERS
71 GF Score
Price $8.35
GF Value $5.19
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings ROCE %?

Xeris Biopharma Holdings XERS -3.30% 71 ROCE % is 11.57% as of Mar. 2026. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xeris Biopharma Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 11.57%.

Xeris Biopharma Holdings  (NAS:XERS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xeris Biopharma Holdings ROCE % Related Terms

Xeris Biopharma Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Xeris Biopharma Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings ROCE % Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.86 -33.04 -14.81 -11.83 11.94

Xeris Biopharma Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.46 9.45 12.79 27.63 11.57
XERS
71GF Score
Xeris Biopharma Holdings Inc XERS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xeris Biopharma Holdings ROCE % Calculation

Xeris Biopharma Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=29.638/( ( (323.06 - 100.443) + (383.527 - 109.574) )/ 2 )
=29.638/( (222.617+273.953)/ 2 )
=29.638/248.285
=11.94 %

Xeris Biopharma Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=31.664/( ( (383.527 - 109.574) + (392.013 - 118.593) )/ 2 )
=31.664/( ( 273.953 + 273.42 )/ 2 )
=31.664/273.6865
=11.57 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 11.57% mean?
Xeris Biopharma Holdings (XERS) has a ROCE % of 11.57% as of Mar. 2026.
Is Xeris Biopharma Holdings' ROCE % too high?
Xeris Biopharma Holdings' current ROCE % is 11.57%. The Drug Manufacturers industry median ROCE % is 7.04. Xeris Biopharma Holdings' value of 11.57% is 64.3% above this industry median. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' ROCE % compare to PAHC and PRGO?
Xeris Biopharma Holdings' ROCE % of 11.57% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. Xeris Biopharma Holdings' value of 11.57% is 64.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current ROCE % of 11.57% is 64.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current ROCE % is 11.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current ROCE % is 11.57% and 64.3% above the Drug Manufacturers industry median of 7.04. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current ROCE % is 11.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

  • ROCE %: 11.57%
  • GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
  • GF Score™: 71/100 with 6 warning signs
  • Industry Position: 64.3% above the Drug Manufacturers median

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges 0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for XERS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.35
Price
$5.19
GF Value